Efficacy of combined treatment of intramuscular testosterone injection and testosterone ointment application for late-onset hypogonadism: an open-labeled, randomized, crossover study.

Clicks: 367
ID: 47079
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #1 of 23 articles by views in the aging male : the official journal of the international society for the study of the aging male

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The best method for administering testosterone replacement therapy (TRT) for late-onset hypogonadism (LOH) remains controversial. This study aimed to compare the efficacy and safety of a combined treatment (CT) involving intramuscular testosterone injection and testosterone ointment application [Glowmin (GL)] with intramuscular injection monotherapy (IMIM). Patients were randomly assigned as follows: Group 1 received IMIM for 12 weeks and CT for 12 weeks and Group 2 received CT for 12 weeks and IMIM for 12 weeks. Patients were then asked about their treatment preferences: (A) IMIM, (B) a combination of IMIM and ointment, or (C) either A or B. Patients ( = 43) completed the study without any adverse effects. No significant differences between each treatment period were found. In Group 1, most patients chose B ( = 13) while in Group 2, most chose A ( = 10). In each group, patients preferred the second treatment phase; however, statistical significance was not reached between A and B (Group 1,  = 0.11 and Group 2,  = 0.47, respectively). TRT by CT is compatible with TRT by IMIM. Patients who cannot continue TRT because of polycythemia from IMIM may be suited to CT.
Reference Key
narukawa2019efficacythe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Narukawa, Tsukasa;Soh, Jintetsu;Kanemitsu, Noriyuki;Harikai, Shunji;Ukimura, Osamu;
Journal the aging male : the official journal of the international society for the study of the aging male
Year 2019
DOI
10.1080/13685538.2019.1666814
URL
Keywords
late-onset hypogonadism intramuscular testosterone injection polycythemia testosterone ointment testosterone replacement therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.